NAV
$18.03
AUM
$75.4M
Expense Ratio
-
Dividend Yield
0.00%
Beta
1.18
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +7.67% | +6.55% | +13.55% | +20.63% | +9.64% | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | PAGP | Plains GP Holdings LP Class A | 41.03% |
| 2 | ACHV | Achieve Life Sciences Inc | 9.94% |
| 3 | MIST | Milestone Pharmaceuticals Inc | 6.30% |
| 4 | ABEO | Abeona Therapeutics Inc | 3.83% |
| 5 | DCTH | Delcath Systems Inc | 3.73% |
| 6 | CORT | Corcept Therapeutics Inc | 3.48% |
| 7 | PHAT | Phathom Pharmaceuticals Inc Ordinary shares | 3.17% |
| 8 | CLDX | Celldex Therapeutics Inc | 2.46% |
| 9 | OCS | Oculis Holding AG | 2.03% |
The fund is an actively managed exchange-traded fund. The Sub-Adviser concentrates the fund's investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The fund is non-diversified.
Inception Date: 2023-02-07